Table of Content

Introduction
Executive Summary
Vasomotor symptoms: Overview
• Causes
• Mechanism of Action
• Signs and Symptoms
• Diagnosis
• Disease Management
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Vasomotor symptoms – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
• Vasomotor symptoms companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Vasomotor symptoms Collaboration Deals
• Company-Company Collaborations (Licensing / Partnering) Analysis
• Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
• Comparative Analysis
Estetrol: Mithra Pharmaceuticals
• Product Description
• Research and Development
• Product Development Activities
Mid Stage Products (Phase II)
• Comparative Analysis
NT-814: NeRRe Therapeutics
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report?..
Early Stage Products (Phase I)
• Comparative Analysis
MLE-301: Millendo Therapeutics
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report?..
Pre-clinical and Discovery Stage Products
• Comparative Analysis
Drug Name: Company Name
• Product Description
• Research and Development
• Product Development Activities
Inactive Products
• Comparative Analysis
Vasomotor symptoms Key Companies
Vasomotor symptoms Key Products
Vasomotor symptoms- Unmet Needs
Vasomotor symptoms- Market Drivers and Barriers
Vasomotor symptoms- Future Perspectives and Conclusion
Vasomotor symptoms Analyst Views
Vasomotor symptoms Key Companies
Appendix



List of Figures


Figure 1 Total Products for Vasomotor symptoms
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products


List of Tables


Table 1 Total Products for Vasomotor symptoms
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products